---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-126349"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:30:44.708181+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Repligen Q1 revenue falls 17% to $151M; GAAP EPS $0.04, adjusted EPS $0.28

## Summary
- Q1 revenue $151.3M, down from $182.7M YoY; GAAP net income $2.1M ($0.04 diluted EPS) vs $28.8M ($0.51).
- Adjusted net income $15.8M ($0.28 diluted EPS) vs $36.3M ($0.64); adjusted gross margin 48.6% vs 55.2%.
- New modalities revenue up 16% YoY; Filtration (non-COVID) up 12% YoY; book-to-bill 0.99 (Q1), 1.03 (nine-month).
- FY2024 guidance reaffirmed: revenue $620M-$650M, adjusted EPS $1.42-$1.49, adjusted op margin 13%-14%.
- Cash and investments $780.6M as of March 31, 2024; Metenova added over $5M revenue in Q1.

## SEC filing metadata
- accession: 0001193125-24-126349
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312524126349/0001193125-24-126349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312524126349/d780642d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-126349
- JSON: https://secwatch.observer/filing/0001193125-24-126349.json
- Plain text: https://secwatch.observer/filing/0001193125-24-126349.txt

## Key facts
- Earnings Releases
  REPLIGEN CORP reported first quarter of 2024, covering the three-month period ended March 31, 2024 results: revenue $151.3 million, net income $2.1 million, EPS $0.04. Guidance reaffirmed.
  - Period: first quarter of 2024, covering the three-month period ended March 31, 2024
  - Revenue: $151.3 million
  - Net income: $2.1 million
  - EPS: $0.04
  - Guidance: reaffirmed
  - Result: reported results
  source text: Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2024 Financial Results • Reports first quarter revenue of $151 million • Increased new modalities revenue by 16% year-over-year • Increased Filtration (non-COVID) revenue by 12% year-over-year • Achieved a nine-month book-to-bill ratio of 1.03
  evidence_url: https://www.sec.gov/Archives/edgar/data/730272/000119312524126349/0001193125-24-126349-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.